Nodular lymphocyte predominant Hodgkin’s lymphoma presenting as severe hypercalcaemia: A case report

Ikram A. Burney, V. Nirmala, Mansour S. Al-Moundhri, Nicholas J. Woodhouse

Research output: Contribution to journalArticle

Abstract

Nodular lymphocyte predominant Hodgkin’s lymphoma (NLPHL) is a recently described type of Hodgkin’s lymphoma (HL) and accounts for 5-6% of all the cases of HL. Here we report the case of an elderly man who presented to Sultan Qaboos University Hospital, Oman, with severe hypercalcemia, and was diagnosed to have stage IV NLPHL. Although the incidence of hypercalcemia is estimated to be between 1-5% in classical HL, to our knowledge this is the first report of NLPHL presenting with severe hypercalcemia. The patient responded to the anti-CD20 monoclonal antibody, Rituximab, and has been in clinical remission for more than 3 years.

Original languageEnglish
Pages (from-to)247-251
Number of pages5
JournalSultan Qaboos University Medical Journal
Volume7
Issue number3
Publication statusPublished - Dec 1 2007

Fingerprint

Hypercalcemia
Hodgkin Disease
Oman
Monoclonal Antibodies
Incidence

Keywords

  • Case Report
  • Hodgkin’s Lymphoma
  • Hypercalcemia
  • Monoclonal antibody
  • Oman
  • Rituximab
  • Thrombocytopenia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nodular lymphocyte predominant Hodgkin’s lymphoma presenting as severe hypercalcaemia : A case report. / Burney, Ikram A.; Nirmala, V.; Al-Moundhri, Mansour S.; Woodhouse, Nicholas J.

In: Sultan Qaboos University Medical Journal, Vol. 7, No. 3, 01.12.2007, p. 247-251.

Research output: Contribution to journalArticle

@article{3b0c937e643244acb9f65879586141f1,
title = "Nodular lymphocyte predominant Hodgkin’s lymphoma presenting as severe hypercalcaemia: A case report",
abstract = "Nodular lymphocyte predominant Hodgkin’s lymphoma (NLPHL) is a recently described type of Hodgkin’s lymphoma (HL) and accounts for 5-6{\%} of all the cases of HL. Here we report the case of an elderly man who presented to Sultan Qaboos University Hospital, Oman, with severe hypercalcemia, and was diagnosed to have stage IV NLPHL. Although the incidence of hypercalcemia is estimated to be between 1-5{\%} in classical HL, to our knowledge this is the first report of NLPHL presenting with severe hypercalcemia. The patient responded to the anti-CD20 monoclonal antibody, Rituximab, and has been in clinical remission for more than 3 years.",
keywords = "Case Report, Hodgkin’s Lymphoma, Hypercalcemia, Monoclonal antibody, Oman, Rituximab, Thrombocytopenia",
author = "Burney, {Ikram A.} and V. Nirmala and Al-Moundhri, {Mansour S.} and Woodhouse, {Nicholas J.}",
year = "2007",
month = "12",
day = "1",
language = "English",
volume = "7",
pages = "247--251",
journal = "Sultan Qaboos University Medical Journal",
issn = "2075-051X",
publisher = "Sultan Qaboos University",
number = "3",

}

TY - JOUR

T1 - Nodular lymphocyte predominant Hodgkin’s lymphoma presenting as severe hypercalcaemia

T2 - A case report

AU - Burney, Ikram A.

AU - Nirmala, V.

AU - Al-Moundhri, Mansour S.

AU - Woodhouse, Nicholas J.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Nodular lymphocyte predominant Hodgkin’s lymphoma (NLPHL) is a recently described type of Hodgkin’s lymphoma (HL) and accounts for 5-6% of all the cases of HL. Here we report the case of an elderly man who presented to Sultan Qaboos University Hospital, Oman, with severe hypercalcemia, and was diagnosed to have stage IV NLPHL. Although the incidence of hypercalcemia is estimated to be between 1-5% in classical HL, to our knowledge this is the first report of NLPHL presenting with severe hypercalcemia. The patient responded to the anti-CD20 monoclonal antibody, Rituximab, and has been in clinical remission for more than 3 years.

AB - Nodular lymphocyte predominant Hodgkin’s lymphoma (NLPHL) is a recently described type of Hodgkin’s lymphoma (HL) and accounts for 5-6% of all the cases of HL. Here we report the case of an elderly man who presented to Sultan Qaboos University Hospital, Oman, with severe hypercalcemia, and was diagnosed to have stage IV NLPHL. Although the incidence of hypercalcemia is estimated to be between 1-5% in classical HL, to our knowledge this is the first report of NLPHL presenting with severe hypercalcemia. The patient responded to the anti-CD20 monoclonal antibody, Rituximab, and has been in clinical remission for more than 3 years.

KW - Case Report

KW - Hodgkin’s Lymphoma

KW - Hypercalcemia

KW - Monoclonal antibody

KW - Oman

KW - Rituximab

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=85040038586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040038586&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85040038586

VL - 7

SP - 247

EP - 251

JO - Sultan Qaboos University Medical Journal

JF - Sultan Qaboos University Medical Journal

SN - 2075-051X

IS - 3

ER -